# **United States Securities and Exchange Commission**

Washington, D.C. 20549

# Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )\*

# Phathom Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share (Title of Class of Securities)

71722W107 (CUSIP Number)

December 31, 2019 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☑ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	Names o	f Re	porting Persons
	Tadata	ka	Yamada
2	Check th	e A	ppropriate Box if a Member of a Group
	(a) 🗆	(t	o)
3	SEC Use	On	ly
4	Citizensh	ip c	or Place of Organization
	United	Sta	ates
		5	Sole Voting Power
	umber of Shares		1,686,704
		6	
	neficially wned by		0
	Each	7	
	eporting Person		1,686,704
	With	8	
	<b>1</b>		0
9	Aggregat	e A	mount Beneficially Owned by Each Reporting Person
	1,686,7	04	
10	Check if	the	Aggregate Amount in Row (9) Excludes Certain Shares
	Not Ap	nli	cable
11			lass Represented by Amount in Row 9
	6.9%		
12		Repo	orting Person
	IN		
	111		

Schedule 13G

CUSIP No. 71722W107

Page 2 of 5

CUSIP No. 71722W107	Schedule 13G	Page 3 of 5
---------------------	--------------	-------------

#### ITEM 1. (a) Name of Issuer:

Phathom Pharmaceuticals, Inc. (the "Issuer")

#### (b) Address of Issuer's Principal Executive Offices:

2150 E. Lake Cook Road, Suite 800 Buffalo Grove, Illinois

# ITEM 2. (a) Name of Person Filing:

This statement is filed on behalf of Tadataka Yamada (the "Reporting Person").

#### (b) Address or Principal Business Office:

The business address of the Reporting Persons is 2150 E. Lake Cook Road, Suite 800, Buffalo Grove, Illinois.

#### (c) Citizenship of each Reporting Person is:

The Reporting Person is a citizen of the United States.

#### (d) Title of Class of Securities:

Common Stock, \$0.0001 par value per share ("Common Stock").

#### (e) CUSIP Number:

71722W107

#### ITEM 3.

Not applicable.

#### ITEM 4. Ownership.

The ownership information below represents beneficial ownership of Common Stock of the Issuer as of the date hereof, based upon 24,526,537 shares of Common Stock outstanding as of November 23, 2019.

#### (a) Amount beneficially owned:

The Reporting Person is the record holder of 1,686,704 shares of Common Stock.

CUSIP No. 71722W107 Schedule 13G Page 4 of 5
--

# (b) Percent of class: 6.9%

#### (c) Number of shares as to which the person has:

- (i) Sole power to vote or to direct the vote: 1,686,704
- (ii) Shared power to vote or direct the vote: 0
- (iii) Sole power to dispose or to direct the disposition of: 1,686,704
- (iv) Shared power to dispose or to direct the disposition of: 0

### ITEM 5. Ownership of Five Percent or Less of a Class.

Not applicable.

### ITEM 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

# ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

#### ITEM 8. Identification and Classification of Members of the Group.

Not applicable.

#### ITEM 9. Notice of Dissolution of Group.

Not applicable.

#### ITEM 10. Certification.

Not applicable.

CUSIP No. 71722W107 Schedule 13G Page 5 of 5
--

# SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Date:** February 10, 2020

/s/ Tadataka Yamada

Tadataka Yamada